A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Required: ALK wild-type

Required: EGFR wild-type

Must have received: platinum-based chemotherapy — HNSCC Arm

Disease progression to platinum-containing chemotherapy

Must have received: anti-PD-1 therapy — HNSCC Arm

Failure to anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination

Must have received: anti-cancer therapy — Melanoma Arm

must have received no more than 3 prior regimens for advanced or metastatic disease

Must have received: anti-cancer therapy — Sarcoma Arm

must have received no more than three lines of prior anti-cancer therapies

Must have received: anti-cancer therapy — cSCC Arm

must have received no more than 3 prior regimens for advanced or metastatic disease

Must have received: anti-cancer therapy — NSCLC Arm

must have received at least one line but no more than three lines of prior anti-cancer therapies

Cannot have received: oncolytic virus (T-VEC)

Prior treatment with another OV (including T-VEC)

Cannot have received: tumor vaccine

Prior treatment with ... tumor vaccines

Cannot have received: cellular therapy

Prior treatment with ... cellular therapy

Cannot have received: gene therapy

Prior treatment with ... gene therapy

Cannot have received: anti-PD-1 therapy

Exception: in combination with IL-12

Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12

Cannot have received: anti-PD-1 therapy

Exception: intolerance or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease

Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease